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Abstract Nuclear receptor coactivator 4 (NcoA4), also
known as androgen receptor-associated protein 70
(ARA70), was initially discovered as a component of Ret-
Fused Gene expressed in a subset of papillary thyroid car-
cinomas. Subsequent studies have established NcoA4 as a
coactivator for a variety of nuclear receptors, including
peroxisome proliferator activated receptors a and c, and
receptors for steroid hormones, vitamins D and A, thyroid
hormone, and aryl hydrocarbons. While human NcoA4 has
both LXXLL and FXXLF motifs that mediate p160 coac-
tivator nuclear receptor interactions, this ubiquitously
expressed protein lacks clearly defined functional domains.
Several studies indicate that NcoA4 localizes predominantly
to the cytoplasm and affects ligand-binding specificity of the
androgen receptor, which has important implications for
androgen-independent prostate cancer. Two NcoA4 vari-
ants, which may exert differential activities, have been
identified in humans. Recent studies suggest that NcoA4
may play a role in development, carcinogenesis, inflam-
mation, erythrogenesis, and cell cycle progression that may
be independent of its role as a receptor coactivator. This
review summarizes what is currently known of the structure,
expression, regulation, and potential functions of this unique
protein in cancerous and non-cancerous pathologies.
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Introduction
Multiple nuclear receptor co-regulatory proteins have been
identified since the prototypical nuclear receptor coacti-
vator, Steroid Receptor Coactivator 1 (SRC1/NcoA1), was
first introduced [1]. These co-regulatory proteins, which
include both coactivators and corepressors, have been
shown to play an important role in modulating physiolog-
ical and pathological functions of steroid hormone and
other nuclear receptors. The p160 family of nuclear
receptor coactivators, of which NcoA1 is a member, has
been best studied; however, recent studies have also
implicated roles for non-p160 coactivators in both devel-
opment and disease progression. Among these is NcoA4,
which has recently been suggested to play a role in
development, carcinogenesis, inflammation, erythro-
genesis, and cell cycle progression. While some of these
activities may involve NcoA4 nuclear receptor co-regulator
function, new data suggest that NcoA4 may have additional
activities independent of this function.
NcoA4 was initially discovered as a component of Ret
Fused Gene (RFG), a novel fusion protein expressed in
papillary thyroid carcinoma, that combines the N-terminal
region of NcoA4 with the constitutively active tyrosine
kinase domain of the ret oncogene (Fig. 1) [2]. Yeh and
Chang [3] first described a function for the intact NcoA4
gene product in 1996. In this study, NcoA4 was identified
in a yeast two-hybrid screen as an androgen receptor (AR)
interacting protein and was shown to potentiate AR tran-
scriptional activity [3]. Based upon these findings, NcoA4
was referred to as AR-associated protein 70 (ARA70) since
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it was initially thought to be AR-specific. Subsequent
studies, however, indicated that NcoA4 interacted with and
regulated the function of additional nuclear receptors
including estrogen (ER) [4], progesterone (PR) [5], glu-
cocorticoid (GR) [5], vitamin D (VDR) [6], thyroid
hormone (TR) [7], peroxisome proliferator-activated a and
c (PPARac) [8, 9], and aryl hydrocarbon (AhR) [10, 11]
receptors. This review summarizes what is currently known
about the structure, expression, regulation, and potential
coactivator and non-coactivator functions of this unique
protein.
Tissue distribution of NcoA4 expression
NcoA4 is ubiquitously expressed in adult mouse tissues
including adrenal gland, heart, kidney, lung, intestine,
spleen, skeletal muscle, and brain [3, 11, 12]. In contrast,
NcoA4 transcripts are not detected in cerebral cortex [3].
There is some disagreement regarding NcoA4 expression
in the liver. While Yeh and Chang [3] report a lack of
hepatic expression, as determined by northern blot analy-
sis, transcripts and protein have been detected by in situ
hybridization, RT-PCR, western blot analysis and immu-
nohistochemistry [11, 12].
NcoA4 protein has also been detected in both female
(uterus and ovary) and male (prostate, testis, seminal ves-
icles, and epididymis) murine reproductive tissues [11, 13].
NcoA4 is highly expressed in mouse ovarian surface epi-
thelial (OSE) cells compared to other ovarian cell types
[14]. Gene expression profiling of OSE cells from mice at
different reproductive states indicated the highest NcoA4
expression on the evening of pro-estrus compared to either
estrus, mid-pregnancy or juvenile stages, suggesting a role
of reproductive hormones in regulating its expression.
NcoA4 expression has also been detected in murine
oocytes [11, 15] and in pre-implantation embryos [16].
A gene expression profiling study comparing the ectopla-
cental cone region of E7.5 conceptuses to mature E17.5
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Fig. 1 Schematic representation of human NcoA4 variants,
ARA70N, and RFG/PTC3. Ensembl Human Genome Browser
software indicates the NCOA4 gene consists of 10 exons. The full-
length NcoA4 cDNA encodes a protein of 614 amino acids (NcoA4a).
Conserved ARA70 domain I (amino acids 37–167) and domain II
(amino acid 138–332) are shown as hatched areas and include a
FXXLF and LXXLL motif. The FXXLF motif located at amino acids
328–332 is involved in interaction with AR and PR. The LXXLL
motif located at amino acids 92–96 is involved in interaction with
VDR, TR and PPARc. Amino acids 231–321 and 441–556 are
necessary for optimal AhR coactivation. The shorter NcoA4 variant
(NcoA4b) lacks internal amino acids 238–556 of NcoA4a and lacks
the FXXLF motif and most of ARA70 domain II. ARA70N consists
of the first 401 amino acids of NcoA4a and thus contains both the
LXXLL and the FXXLF motifs. Ret Fused Gene (RFG/PTC3) is a
fusion protein consisting of the first 238 amino acids of NcoA4 joined
to amino acid 712 of the C-terminal region of RET. This fusion
protein thus contains the RET tyrosine kinase domain at amino acids
724–1005
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NcoA4 listed amongst E7.5 stage-specific genes [17].
These studies raise the possibility that NcoA4 may play a
role in early embryo and placental development.
A dynamic profile of NcoA4 expression was detected in
cardiac, hepatic, and lung tissue during mouse develop-
ment. Within cardiac tissue, immunostaining was detected
from E11.5 to E13.5, whereas a biphasic pattern was
detected in hepatic tissue. In lung tissue, the highest NcoA4
expression was detected from E12.5 to E14.5, while
staining was undetectable at later stages up to E18.5 [11].
At present, the reasons for the differential expression of
NcoA4 at different embryonic stages and tissues are not
known. The expression pattern is consistent with a poten-
tial contribution to cell proliferation and/or differentiation
during development.
Few studies have examined NcoA4 expression in adult
or developing human tissues. Gene expression profiling
studies indicate human metaphase II oocytes express
NcoA4, comparable to what has been reported in mice
[18]. Similar studies also indicate NcoA4 expression in the
uterine myometrium, with higher levels observed in tissues
from pregnant compared to non-pregnant women [19].
Expression of NcoA4 mRNA was also detected by real-
time RT-PCR in human luteinized granulosa cells obtained
at oocyte retrieval from 198 in vitro fertilization patients
[20], and was positively correlated with ERa and aromatase
expression. Thus, NcoA4 may contribute to hormonal
regulation of follicles.
Structural properties of NcoA4
The gene encoding NcoA4 is found on chromosome
10q11.2 in humans and 14B in mice. The gene consists of
ten exons in both species, resulting in mature transcripts
encoding proteins of 614 and 625 amino acids in human and
mouse, respectively (http://www.ensembl.org/). Analysis of
the NcoA4 amino acid sequence indicates this protein lacks
known structural or functional domains with the exception
of an N-terminus putative coiled–coil protein–protein
interaction domain. Amino acids 37–167 and 198–332 of
the human NcoA4 sequences correspond to evolutionarily
conserved regions referred to as ARA70 family domains I
and II, respectively. Blastp analysis of either the full-length
NcoA4 sequence or ARA70-I or -II domains failed to
identify related proteins within the human genome, indi-
cating that NcoA4 lacks structurally related family
members; however, orthologs exist throughout metazoans
[21], suggesting conservation of function.
Two NcoA4 transcript variants have been identified to
date in humans: a full-length NcoA4 cDNA that encodes a
614 amino acid protein (NcoA4a) with an estimated
molecular weight of 70 kDa [3] and a shorter cDNA
possessing an internal 985 base pair deletion encoding a 286
amino acid protein (NcoA4b) with an estimated molecular
weight of 35 kDa [22] (Fig. 1). Multiple variants of rodent
NcoA4 transcripts have been submitted to the NCBI data-
base; however, their potential translation and function have
not yet been explored. In addition to these, we recently dis-
covered a novel murine NcoA4 transcript expressed during
early mouse development, consisting of an internal 586
nucleotide deletion corresponding to a lack of exons 4, 5, 6,
and 7 and portions of exons 3 and 8 [11]. While expression of
protein product for this variant was not detected, a 55-kDa
NcoA4 immunoreactive protein was identified that may
represent an additional variant. Expression of a shorter
uncharacterized NcoA4 transcript variant by northern blot
analysis has also been reported in rat testis [22]. The dis-
covery of these rodent variants raises the possibility of
additional human variants encoding proteins with diverse
functions that could have an important physiological impact.
Most NcoA4-nuclear receptor interactions have been
demonstrated using NcoA4a or the N-terminal domain of
NcoA4 consisting of amino acids 1–401 (ARA70N;
Fig. 1). Human NcoA4a and ARA70N contain two signa-
ture nuclear receptor interaction motifs: an LXXLL
(LYSLL, where L = leucine, Y = tyrosine and S = ser-
ine) motif, initially identified in p160 family members [23],
located in the N-terminal region (92–96 amino acids); and
an FXXLF (FKLLF, where F = phenylalanine, K = lysine
and L = leucine) motif at amino acids 328–332 (Fig. 1) [9,
24]. While the LXXLL motif is involved in the interaction
of NcoA4 with PPARc, VDR, and TR [6, 7, 9], the region
involved in the interaction with the ligand binding domain
(LBD) of the AR and PR is located within amino acids
321–441, which contains the FXXLF motif [22, 24–27].
Evidence that the FXXLF motif of NcoA4 is essential for
NcoA4–AR and NcoA4–PR interactions has been provided
by site-directed mutagenesis studies [25, 26, 28]. However,
amino acids flanking the FXXLF motif are also important
for the functional interaction with AR [26, 29]. While both
active androgens, dihydrotestosterone (DHT) and testos-
terone, promote NcoA4–AR interaction [3, 30], Alen et al.
[22] have demonstrated that this interaction also occurs in
the absence of exogenous androgen.
Deletion of amino acids 321–441 of NcoA4 diminishes
the potentiation of AR transactivation by only 50 % of that
achieved with wild-type NcoA4 [24], suggesting that
additional regions of NcoA4 contribute to AR–NcoA4
interaction or to NcoA4 coactivator activity. A study by Hu
et al. [27] has shown that amino acids 1–175 of NcoA4 are
essential for enhancing AR transcriptional activity; how-
ever, this does not require the LXXLL motif. It is important
to note that this region does not appear to contribute to the
physical interaction with AR. Furthermore, inclusion of
the C-terminal region of NcoA4 (amino acids 500–614)
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diminishes NcoA4–AR interaction as compared to
ARA70N [24], suggesting the C-terminal region harbors
inhibitory sequences.
Studies indicate that NcoA4 interacts with multiple
domains of AR, which may involve different regions of
NcoA4. Yeast two-hybrid studies have demonstrated that
NcoA4 interaction with the AR LBD is further enhanced
by the presence of the AR DNA binding domain (DBD)
[31, 32]. In addition, maximum induction of AR tran-
scriptional activity by NcoA4 requires its interaction with
the N-terminal domain of the AR [24]. Despite lacking the
FXXLF motif and its flanking region, NcoA4b interacts
with AR in addition to other steroid hormone receptors [22,
33]. However, in contrast to full-length NcoA4, NcoA4b
interacts solely with the N-terminal AR domain [33].
Unlike the case with steroid hormone receptors, the
ability of NcoA4 to potentiate AhR signaling does not
appear to involve either the LXXLL or the FXXLF motif or
flanking amino acids 321–441 [10]. Rather, regions within
amino acid sequences 238–321 and 441–566 are most
likely responsible for optimal AhR transactivation. This is
further supported by diminished enhancement of AhR
transcriptional activity by ARA70N and NcoA4b relative
to full-length NcoA4 [10].
The mouse full-length NcoA4 sequence differs notably
from the human sequence in the absence of the LXXLL
motif. Murine NcoA4 contains an FXXLF motif at amino
acids 334–338. Siriett et al. [12] have reported that the
N-terminal region (amino acids 1–501) of mouse NcoA4
interacts directly with the LBD of AR. However, full-
length mouse NcoA4 was not able to interact with this AR
domain, consistent with human NcoA4 [3], which further
supports the existence of an inhibitory sequence located in
the C-terminal region of NcoA4.
Function of NcoA4 as an androgen receptor
co-regulator
NcoA4 is best known for its activity as an AR coactivator
(Table 1). Early studies demonstrated a ligand-dependent
interaction and an increase in AR transcriptional activity by
Table 1 Summary of NcoA4
interacting nuclear receptors
and the impact of NcoA4 on
their transcriptional activity




AR DHT/T/R1881 : [3, 5, 11, 22, 24, 34, 38–
40]




Hydroxyflutamide : [44, 45]
Hydroxyflutamide – [46]
Mutated AR: M745I R1881/E2 : [38]
M745I Progesterone – [38]
M745I Dexamethasone – [38]
M745I Hydroxyflutamide – [38]
T877A Hydroxyflutamide : [46]
E231G/K638M/T857A R1881/E2 : [41]
ER E2 : [4, 3, 40]
PR Progesterone : [3]
GR Dexamethasone : [3]
VDR 1,25-vitamin D : [6]
PPARc 15dJ2 : [9]
RXR 9-cis retinoic acid – [8, 9]
PPARa WY14,643 : [8]
Mutated PPARa:wild type
RXR
WY14,643 and 9-cis retinoic
acid
: [8]
PPARa:RXR WY14,643 and 9-cis retinoic
acid
; [8]
TR T3 ; [48]
AhR TCDD : [10, 11]
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at least 10-fold [3, 34]. However, these studies were per-
formed with ARA70N rather than full-length NcoA4, and
subsequent studies have established that this N-terminal
portion of the protein provides optimal AR interaction and
transactivation enhancement [13, 34–37]. Studies with full-
length NcoA4 generally report lower levels of AR poten-
tiation, in the range of 2- to 6-fold [5, 22, 24, 38–40].
Interestingly, despite lacking the FXXLF motif and flank-
ing residues, NcoA4b is at least as effective an AR
coactivator as NcoA4a [22, 33], likely due to its interaction
with the N-terminal AR domain. Species differences in AR
potentiation by NcoA4 are also likely; we found only a
modest increase in AR transactivation (1.5-fold) by full-
length mouse NcoA4 [11].
A unique aspect of NcoA4 activity at the AR is its
reported ability to diminish ligand specificity (Table 1).
Overexpression of NcoA4 has been shown to enhance AR
transactivation induced by ligands other than active
androgens, which may have negative implications for the
success of hormonal therapies used in the treatment of
prostate cancer. These ligands include 17b-estradiol (E2)
[35, 41, 42], androstene-3b,17b-diol (Adiol) [43], and the
phytoestrogen daidzein [35]. Other ER ligands such as
diethylstilbestrol (DES), estrone, 17a-estradiol, and
tamoxifen fail to induce AR transactivation in the presence
of NcoA4 overexpression, indicating that this effect is
ligand-specific [42]. It is important to note, however, that
these studies were performed using ARA70N and are
reliant on cell-based reporter assays. The effect of full-
length NcoA4 has only been examined in a single study,
which found only a marginal effect on E2-induced AR
transcriptional activity [38]. To date, no study has
addressed whether this effect can be elicited with an
endogenous AR target gene.
In addition to ligand specificity, NcoA4 overexpression
reverses the antagonistic activity of hydroxyflutamide
(Table 1), an AR antagonist widely used in the treatment of
prostate cancer. An agonist effect of hydroxyflutamide
induced by ARA70N has been demonstrated using pro-
moter gene assays [44, 45], and is abolished by
overexpression of dominant-negative NcoA4 [36]. While
this finding has important implications for the development
of failed anti-androgen treatment, Brooke et al. [46] found
that ARA70N enhances agonist activity of hydroxyfluta-
mide only with human prostate cancer LNCaP cell AR,
which contains a point mutation (T877A) within the LBD.
No effect was observed with wild-type AR, which is in
direct contrast to evidence provided by Yeh et al. [45].
The mutation status of the AR has been shown to
influence the potentiation by NcoA4 in a site- and ligand-
specific manner (Table 1). For example, NcoA4 enhances
estrogen, but not low dose androgen, activation of M745I-
mutated AR, a mutation associated with Complete
Androgen Insensitivity Syndrome [38]. Hypersensitivity of
this receptor to estrogen, coupled with its lower affinity for
androgens, is thought to result in the lack of induction of
male sexual differentiation by this mutated receptor. Gain-
of-function mutations in AR occur during prostate cancer
progression, and several of these have been recapitulated in
mouse models of prostate cancer to examine their signifi-
cance (as reviewed by [47]). Using the autochthonous
transgenic adenocarcinoma of mouse prostate (TRAMP)
model, Han et al. [41] identified somatic AR mutations
associated with emergence of androgen-independent pros-
tate cancer. Of three mutations examined, ARA70N was
able to increase the activity of E231G-mutated AR in
response to either androgen or estrogen ligands, whereas
AR-associated protein 160 (ARA160), another AR coacti-
vator, enhanced the activity only of androgens [41]. These
studies demonstrate that coactivators differentially modu-
late mutated ARs.
Function of NcoA4 as a co-regulator of other nuclear
receptors
NcoA4 interacts with several members of the thyroid and
steroid hormone receptor superfamily including PR, ER,
GR, VDR, PPARc, PPARa, and TR (Table 1) [4, 6, 8, 9,
22, 48, 49]. While only minimal increases in ligand-acti-
vated PR, ER, and GR transcriptional activity (less than
twofold) by NcoA4 overexpression have been reported [3,
4, 40], higher activity at VDR, PPARc, and PPARa has
been shown [6, 8, 9]. In addition, NcoA4 activity at the
PPARa receptor appears to be context-dependent, func-
tioning as a coactivator in the absence of the PPARa
heterodimer partner retinoic X receptor (RXR), and as a
repressor in the presence of RXR [8]. Repressor activity of
NcoA4 has also been reported for TR [48]. The impact of
the NcoA4b variant on these receptors has not yet been
addressed, with the exception of the ER, where it has been
shown to have similar efficacy as NcoA4a [40].
NcoA4 also interacts with both AhR and its heterodi-
meric partner AhR nuclear translocator (ARNT) in a ligand-
independent manner (Table 1). NcoA4a enhances the AhR
transcriptional activity by 3.2-fold in the presence of
ligand. In contrast to thyroid and steroid hormone receptor
family members, ARA70N and NcoA4b variant were
less effective than NcoA4a [10]. In addition, full-length
murine NcoA4 was shown to be a more potent coactivator
for the AhR than for the AR, with overexpression aug-
menting the transcriptional activity of AhR by 5-fold and
AR by only 1.5-fold [11]. Thus, NcoA4 functions as a
co-regulator of diverse nuclear receptor transcription reg-
ulators with differences in activity between the two human
variants.
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Involvement of NcoA4 in nuclear receptor competition
The interaction of NcoA4 with multiple nuclear receptors
raises the possibility that its sequestration by one receptor
type might alter the activity of other NcoA4 interacting
receptors, with this competition representing a form of
cross-talk. Studies indicate that AR competes with AhR,
VDR, and PPARc/RXR for NcoA4 availability [6, 9, 10].
NcoA4 may cooperate with other coactivators, such as AR-
associated protein 54 (ARA54), ARA160, retinoblastoma
(Rb), breast cancer susceptibility gene 1 (BRCA1), super-
villin (SV), and four and a half LIM 2 (FHL2), to
synergistically or additively induce receptor transcriptional
activity. Additive effects of NcoA4 with Rb and ARA54
have been shown in DU145 cells [50, 51]. Synergistic
effects of NcoA4 have been reported with BRCA1, SV, and
ARA160 [30, 52, 53], suggesting that NcoA4 may act
through a unique mechanism. Synergistic activity of
NcoA4 has also been found with FHL2 potentiation of the
AhR [54].
The interaction between NcoA4 and AR can be mod-
ulated by protein kinases. Blockage of PI(3)K/Akt by
dominant-negative Akt or LY294002, a specific PI(3)K
antagonist, enhances the impact of ARA70N on AR
transcriptional activity [55]. These effects were reversed
by addition of constitutively active Akt raising the
possibility that NcoA4 may be modulated by its phos-
phorylation status. However, since PI(3)K/Akt also
phosphorylates AR, it is not clear from these studies
whether the effect might be due to phosphorylation of AR
or NcoA4. While several putative phosphorylation sites
exist for NcoA4, phosphorylation of this protein has not
as yet been addressed.
NcoA4 lacks intrinsic histone acetyltransferase (HAT)
activity [22]; however, both human NcoA4 variants inter-
act with p/CAF [p300/cAMP response element binding
protein (CREB) binding protein (CBP)-associated factor],
which contains intrinsic HAT activity [22, 34]. Thus, it is
possible that NcoA4 may increase the association of p/CAF
with the receptor complex.
The predominant cytoplasmic localization of NcoA4,
even in the presence of receptor ligands [4, 10, 27, 56, 57],
suggests that NcoA4 may act differently than the classical
p160 steroid receptor coactivators. NcoA4 may be involved
in cytoplasmic events that increase the receptor activity by
altering the expression, nuclear translocalization, and sta-
bility of the receptor [27]. Indeed, the half-life of AR was
increased from 0.8 to 2.3 h in the presence of NcoA4, as
demonstrated by pulse chase experiments [27]. Addition-
ally, the predominant cytoplasmic localization of NcoA4
raises the possibility of other functional roles independent
of a role as a nuclear receptor coactivator.
Additional functions of NcoA4
Several coactivators have been found to have functions in
addition to their role as nuclear receptor transcriptional
modulators. An example of this is SRC3, originally referred
to as Amplified in Breast Cancer 1. While this coactivator
was initially found to enhance ER signaling, further studies
have indicated a promoting role in epithelial–mesenchymal
transition (EMT) necessary for metastasis and invasion (as
reviewed by Lydon and O’Malley [58]). Moreover, a
truncated SRC3 isoform acts to bridge the epidermal growth
factor receptor to focal adhesion kinase at the plasma
membrane, thereby promoting migration of the cancer cells
[59]. Several studies indicate additional roles for NcoA4,
some of which may be independent of its activity as a
nuclear receptor coactivator.
Role in proliferation, migration and invasion
Effects of NcoA4 on cell proliferation have been reported
that are independent of steroid hormone activity [33, 40].
Despite the fact that both NcoA4a and b function as AR
coactivators in cell-based reporter assays, full-length
NcoA4 suppressed androgen-induced proliferation of AR-
expressing prostate cancer cell lines in vitro and in vivo
[32, 33]. In contrast, the NcoA4b variant enhanced cell
proliferation and colony-forming ability. Similar effects
were found in MCF-7 breast cancer cells [40]. While
expression of NcoA4a decreased cell proliferation,
NcoA4b expression increased cell proliferation and colony
formation independent of steroid hormone.
Despite the similar effects of the two variants in breast
and prostate cancer cell lines, the underlying mechanisms
appear to differ. In LNCaP cells, 57 % of cells transfected
with NcoA4b were in the S phase as compared to 16 % of
control cells. This increased cell cycle progression was
accompanied by increased cyclin A and decreased p27kip1
expression with no effect on cyclin B1 or p21 [33].
NcoA4a overexpression in these cells had no effect on cell
cycle progression, but was associated with activated cas-
pase 3 and Bax and decreased Bcl-xL, consistent with
increased apoptosis [32]. In comparison, overexpression of
NcoA4b in MCF7 cells resulted in decreased p27kip1 and
increased cyclin B1 and skp2 levels [40]. NcoA4a over-
expression in these cells had an opposite effect: increased
p27kip1 and decreased skp2 expression [40]. The expression
of genes related to cell survival were not examined.
NcoA4b and NcoA4a have also been reported to affect
the motility of LNCaP and MCF7 cells. NcoA4a inhibited,
whereas NcoA4b promoted, migration of LNCaP cells
through a matrigel barrier in an androgen-independent
manner [32, 33]. In MCF7 cells, only NcoA4b affected
3900 A. Kollara, T. J. Brown
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(increased) migration in a hormone-independent manner
[40]. However, in the presence of androgen, both variants
inhibited migration, whereas in the presence of estrogen,
both variants promoted migration. These studies demon-
strate that NcoA4 affects cell migration independently of
the presence of steroid hormone, suggesting involvement
of non-coactivator NcoA4 activity; however, since these
effects were altered by the presence of steroid hormones, a
coactivator function cannot be completely excluded.
Potential role of NcoA4 in cell division
The recently discovered association of NcoA4 with
microtubules is consistent with a potential co-chaperone
role in facilitating receptor activity. Several hsp90/steroid
receptor interacting proteins have been shown to affect
transcriptional activity of steroid hormone receptors
through their ability to influence subcellular localization
or stability of the receptor [60–65]. AR interaction with
various immunophilins including FK506 binding proteins
has been postulated to modulate its interaction with
dynein and transport along microtubules for nuclear
import [66].
NcoA4 has also been found to localize with the mitotic
spindle apparatus [21] (Fig. 2), raising the possibility of
additional coactivator-independent actions. NcoA4 co-
localizes with tubulin and acetylated tubulin at the mitotic
spindles during metaphase and anaphase. Dynamic changes
in NcoA4 centrosomal distribution, with strong accumu-
lation during interphase and telophase and decreased levels
at metaphase and anaphase, indicate that NcoA4 may play
an important role in cell division [21]. This, together with
NcoA4 staining at midbodies during telophase, is consis-
tent with an action in chromosome segregation and/or
cytokinesis. Thus, an intriguing area for further study is a
potential role of NcoA4 in cell division and/or the main-
tenance of genomic stability. Interestingly, NcoA4 was 1 of
30 genes found by suppression subtractive hybridization
and differential screening to be downregulated during
replicative senescence of 2BS human embryonic lung
fibroblasts [67]. Other downregulated genes identified in
these non-replicative cells encoded proteins involved with
DNA synthesis and RNA processing, cell cycle regulation,
cytoskeleton, protein transportation, cell signaling, and
metabolism, supporting the possible involvement of
NcoA4 in cell division.
Regulation of NcoA4 expression and function
Few studies have addressed the regulation of NcoA4
expression, and a systematic analysis of the NcoA4 pro-
moter region has yet to be presented. However, regulation
by steroid hormones, thyroid hormone, myostatin, and
resveratrol has been suggested by several studies. NcoA4
mRNA expression is increased by DHT and estradiol, as
well as by tetrahydrogestrinone, an anabolic steroid with
potent androgen and progestin effects [68, 69]. Activation
of NcoA4 expression by some but not all adipocyte dif-
ferentiation inducers, including dexamethasone and
3-isobutyl-1-methylxanthine, has been shown in 3T3-L1
preadipocyte cells [70]. These findings suggest regulation
of NcoA4 expression by glucocorticoid receptors and by
cAMP/cGMP, and raise the possibility that NcoA4 may
play a role in early events of adipocyte differentiation.
Upregulation of NcoA4 expression by thyroid hormone




Fig. 2 Localization of NcoA4 to the mitotic spindle. Staining of
T47D human breast cancer cells for NcoA4 (green) and a-tubulin
(red) was visualized by immunofluorescence and examined by
confocal microscopy. Chromatin was visualized by DAPI staining
(blue). Yellow indicates areas of overlapping NcoA4-a-tubulin
staining. a Prophase cell showing punctate NcoA4 staining associated
with microtubules. White arrows indicate mitotic organization
centers. b Metaphase cell showing localization of NcoA4 to mitotic
spindles (yellow arrow). c Anaphase cell showing localization of
NcoA4 to mitotic spindles (yellow arrow). NcoA4 staining is not
observed at the centromere (white arrow) at this stage. d Telophase
cell showing strong NcoA4 staining at the midbodies (red arrow).
Bars 10 lm
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with TRa1 or TRb1, and in liver from thyroidectomized
rats. This regulation appears to be direct as it persists in the
presence of cyclohexamide, and TR binding to response
elements within the NcoA4 promoter region has been
demonstrated by electrophoretic mobility shift assay [48].
Gene expression microarray studies have implicated
additional regulators of NcoA4. Among these are sex-
determining region Y box 4 (SOX4), a highly conserved
transcriptional factor associated with embryonic develop-
ment and oncogenesis, and manganese superoxide
dismutase (SOD2) [71, 72]. Targeted downregulation of
SOX4 in LNCaP cells decreases NcoA4 expression
whereas downregulation of SOD2 increases NcoA4
expression. The effect of SOD2 targeting siRNA was
reversed by N-acetylcysteine treatment, an endogenous
antioxidant, indicating that NcoA4 may be regulated by
reactive oxygen species. Consistent with this idea, Mitchell
et al. [73] has found that the antioxidant resveratrol
decreases NcoA4 expression in LNCaP cells.
Murine NcoA4 is negatively regulated by myostatin, a
member of the transforming growth factor b superfamily
that acts as an inhibitor of skeletal muscle growth [12, 74].
Siriett et al. [12] demonstrated a 1.5-fold increase in
NcoA4 transcripts in the biceps femoris muscle of myost-
atin-null mice compared to wild-type mice. This regulation
was verified in C2C12 primary myoblast cells. In the
absence of exogenous myostatin treatment, NcoA4 mRNA
expression was initiated at 12 h and attained maximum
levels at 72 h following differentiation of these cells,
suggesting that NcoA4 is involved in late stages of muscle
cell differentiation. However, in the presence of myostatin,
NcoA4 expression was not detected at any of the time
points examined under differentiating conditions [12]. The
negative regulation of NcoA4 expression by myostatin, the
pronounced skeletal muscle hypertrophy in myostatin-null
mice, and the increased expression of AR in muscle
hypertrophy [75, 76], are consistent with a coactivator role
of NcoA4 in enhancing AR-mediated muscle cell growth.
Potential involvement of NcoA4 in disease progression
Thyroid cancer
The involvement of NcoA4 as part of the RET/PTC3 fusion
protein in papillary thyroid carcinomas (PTCs) has been
studied extensively. RET/PTC rearrangements occur in
10–20 % of PTCs and are associated with radiation expo-
sure and possible induction of chromosomal fragility
[77, 78]. The RET/PTC3 chromosomal rearrangement
results from the fusion of the constitutively active tyrosine
kinase domain of RET with the N-terminal region of NcoA4
(Fig. 1) residing in the long arm of human chromosome
10q11.2 [79, 80]. The ligand-independent dimerization of
RET/PTC protein leads to chronic stimulation of MAPK
and PI3K-AKT signaling and increased cell proliferation
and transformation in thyroid cells [78, 80]. Transgenic
mice expressing human RET/PTC3 exclusively in the thy-
roid develop thyroid hyperplasia and metastatic cancer [81].
RET/PTC3 is able to activate NF-kB and pro-inflammatory
mediators in thyroid epithelial cells [82]. While this is
known to involve a tyrosine residue within the RET portion
of the fusion protein, a potential role of the NcoA4 sequence
has not yet been determined.
Prostate cancer
Single nucleotide polymorphisms (SNP) in chromosome
10q11 have been associated with prostate cancer, with
some of these SNPs localizing to NcoA4 [32, 83–85].
However, altered expression of NcoA4 in human prostate
cancer has not been firmly established. NcoA4 mRNA and
protein expression has been demonstrated in secondary
prostate cancer cell lines, LNCaP, PC-3, and DU145 [22,
56, 57, 86–89]. Whereas DU145 and LNCaP cells express
only NcoA4a, PC-3 cells also express NcoA4b [56].
Studies examining NcoA4 expression in human prostatic
tissues have yielded conflicting results. Li et al. [90] and
Ligr et al. [32] reported decreased NcoA4 mRNA expres-
sion in both prostate intraepithelial neoplasia, a recognized
precursor lesion for prostate cancer, and malignant prostate
relative to benign prostate, whereas Mestayer et al. [87]
reported similar levels in both normal and malignant
prostate. Ligr et al. [32] further showed that NcoA4 over-
expression in LNCaP cell xenographs suppressed tumor
growth, suggesting a tumor suppressor role of full-length
NcoA4. In contrast, Hu et al. [27] demonstrated increased
NcoA4 protein levels in neoplastic and malignant prostate
compared to benign prostate. Moreover, a more recent
study indicates that NcoA4 expression is increased in
LNCaP cells maintained in the presence of hydroxyfluta-
mide compared to parental cells [91], suggesting that
NcoA4 may play a role in the development of antiandrogen
insensitivity.
NcoA4b protein expression has been demonstrated by
immunohistochemistry in a subset (15 of 30 cases exam-
ined) of prostate cancer cases, with no staining for this
variant observed in any cases of benign prostatic epithe-
lium [33]. Differential localization of the two NcoA4
isoforms was noted, with NcoA4a localizing predomi-
nantly to the nucleus and NcoA4b to the cytoplasm [89],
raising the possibility that the two isoforms may exert
different effects.
NcoA4b expression in LNCaP cells has a pronounced
effect on gene expression profiles. A genome-wide
microarray study identified 953 genes as differentially
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expressed due to NcoA4b expression [33]. These genes
exhibited a greater than 10-fold altered expression level
and encode metabolic factors, growth factors, tumor
suppressors, oncogenes, transcription factors, and cell
adhesion proteins. Genes with the highest fold-increase
included HOXA9 (homeobox A9; 160-fold), HOXD13
(homeobox d13; 108-fold), and GR (98-fold), while genes
with the highest fold-decrease included NEP (endopepti-
dase; 1,717-fold), CDH1 (E-cadherin; 1,266-fold), and
CLDN3 (Claudin 3; 420-fold). Surprisingly, a greater than
1,000-fold decrease in PSA was also detected in NcoA4b-
transfected LNCaP cells. Overall, these findings are con-
sistent with a tumor promoting role of NcoA4b as genes
involved in cell adhesion are decreased whereas genes
involved with proliferation are increased.
Niu et al. [57] have shown by GST pull-down and co-
immunoprecipitation that NcoA4 interacts with PSA and
AR, possibly forming a tripartite complex. Co-localization
of PSA and NcoA4 was observed in the cytosol of high
passage LNCaP cells in the presence of androgen. While
this complex was not detected at the promoter of androgen
target genes, PSA enhanced AR transcriptional activity in
both LNCaP and 22RV1 cells, which was independent of
its protease activity and was significantly inhibited by
silencing NcoA4 expression. Altogether, these studies
indicate the need for further investigations to clarify the
expression and/or distribution of NcoA4 isoforms in pros-
tate cancer.
Breast cancer
The role of ER and PR in breast cancer is well estab-
lished, whereas the role of AR and AhR is not as well
defined. Several studies have investigated the role of
steroid hormone receptor coactivators in breast cancer and
are suggestive of a role for NcoA4. Decreased NcoA4a
mRNA expression in invasive breast cancer relative to
benign and in situ carcinoma has been reported, with a
greater number of metastatic tumors showing decreased
expression [40]. High levels of NcoA4 protein have been
shown in human benign breast epithelium and in situ
breast carcinomas [56]. Variable protein expression was
observed in the invasive carcinomas, with a trend towards
decreased NcoA4 protein expression in Her2/neu-positive
invasive breast tumors (60 % of Her2/neu-positive vs.
33 % of Her2/neu-negative tumors) [56]. Her2/neu stabi-
lizes AR protein and enhances AR signaling [37, 92, 93],
which is generally enhanced by NcoA4 expression.
NcoA4 and AR mRNA expression are positively corre-
lated in invasive breast tumors [94]. Since AR is a
favorable prognostic indicator, and its action in breast
epithelium generally leads to inhibition of cell growth
[95–97], loss of NcoA4 and/or AR in the presence of
Her2/neu could represent more aggressive subtypes of
invasive breast cancer.
Western blot analysis, using protein extracted from
invasive ductal carcinomas and adjacent benign breast
tissue from four patients, revealed expression of NcoA4a
but not NcoA4b in benign tissue, whereas two of the four
carcinomas showed markedly decreased expression of
NcoA4a and detectable NcoA4b expression [56]. These
findings suggest that the two NcoA4 isoforms are differ-
entially expressed in some invasive breast cancers, raising
the possibility of a role in disease progression. Further
studies are thus required to define the actions of NcoA4
isoforms in breast epithelial cells.
NcoA4 expression has been demonstrated in multiple
human breast cancer cell lines with some of these cells
expressing NcoA4b [4, 22, 56, 98]. Increased NcoA4
expression was observed in breast cancer cell lines
undergoing EMT induced by co-culture with bone marrow-
derived mesenchymal stem cells (MSCs) [99]. This study
suggests that NcoA4 may reflect or promote breast cancer
metastasis. Unfortunately, the microarray approach used
did not address whether this effect was isoform-specific.
The effect of NcoA4a and b on mammary gland
development was addressed by Wu et al. [40], who gen-
erated transgenic mice carrying MMTV-driven transgenes
encoding NcoA4a or b. While NcoA4a decreased mam-
mary gland branching, NcoA4b enhanced branching
compared to wild-type mice. In addition, mammary
hyperplasia was observed in 4-week-old virgin and preg-
nant NcoA4b mice, but this did not lead to mammary
tumor development. These studies demonstrate that NcoA4
modulates breast duct arborization in an isoform-specific
manner and plays a role in growth regulation. NcoA4 has
also been implicated in mammary cell proliferation by
studies performed by Hua et al. [100]. Using a gene-tiling
array, they identified NcoA4 as an estrogen-regulated gene
and demonstrated ERa binding to the NcoA4 promoter
region. Knockdown of NcoA4 expression in MCF7 cells
resulted in decreased proliferation under both basal and
estrogen-stimulated conditions, consistent with a role of
NcoA4 in breast epithelial proliferation.
Other cancer types
Altered NcoA4 expression has also been demonstrated in
other cancers, including ovarian, renal, oral, and colorectal.
Using in situ hybridization, we reported upregulated
NcoA4 expression in 17 of 20 human invasive ovarian
epithelial carcinomas as compared to the non-malignant
ovarian surface epithelium [101]. NcoA4 mRNA and pro-
tein is also expressed in human ovarian cancer cell lines
[86]. As androgen has been implicated in ovarian cancer,
these findings raise the possibility that NcoA4 might play a
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coactivator role in the etiology/progression in a subset of
these cancers.
A recent gene expression profiling study identified
NcoA4 as one of the genes upregulated in renal cell car-
cinoma but downregulated in late renal regeneration and
repair. Since chronic renal regeneration and repair in
individuals with polycystic kidney disease can lead to renal
cell carcinoma, these results suggest that NcoA4 expres-
sion may be altered in the progression of this cancer [102].
A role of NcoA4 in this progression has not been explored.
A microarray approach has identified NcoA4 transcript
levels as one of ten candidate serum markers for oral
squamous cell carcinomas (OSCC). An upregulation of
NcoA4 RNA in the serum transcriptome of patients with
OSCC compared to healthy donors was validated by RT-
PCR [103]. While the cell of origin responsible for
increased NcoA4 serum transcripts is not known, a possi-
bility is that they are derived from tumor cells undergoing
cell death/apoptosis.
In colorectal cancer, studies suggest that NcoA4 may
contribute to carcinogenesis associated with loss of epi-
genetic regulation resulting from impaired histone
deacetylase 2 (HDAC2) function and to metastatic pro-
gression. Inactivating mutations of HDAC2 have been
associated with resistance to histone deacetylase inhibitors
in colorectal cancers [104], and Ropero et al. [105] have
established that NcoA4 expression is directly repressed by
HDAC2. Further studies are required to determine if this
increase in NcoA4 is important in the transforming path-
way triggered by HDAC2 mutations. Increased NcoA4
expression was also detected in SW620 relative to SW480
colorectal cancer cells [106]. These cell lines were derived
from the same patient, with SW480 cells isolated from the
primary tumor and SW620 cells isolated from a lymph
node metastasis. The increased expression of NcoA4 in the
metastatic cell line raises the possibility that NcoA4 may
be involved in later progression of the disease or reflect a
more aggressive cell line.
Non-cancerous diseases
Altered NcoA4 expression has been shown in polycystic
ovarian syndrome (PCOS) and alopecia, two androgen-
associated pathologies. PCOS is associated with oligo-
menorrhea or amenorrhea, androgen excess, and a high
incidence of uterine endometrial hyperplasia. Two studies,
which have examined the possibility that NcoA4 expres-
sion is altered in the endometrium of PCOS patients, have
yielded contradictory results. Quezada et al. [107] reported
increased NcoA4 mRNA and protein in endometrial epi-
thelial cells of women with PCOS compared to control
women. However, Villavicencio et al. [108] did not
observe a difference in NcoA4 protein levels in the
epithelium of women with PCOS, PCOS and hyperplasia,
hyperplasia only, or normal endometrium. While the rea-
sons for the disparity in these study results is not apparent,
in both studies NcoA4 was localized predominantly within
the cytoplasm of the epithelial and stromal cells [107, 108].
Possible involvement of NcoA4 in androgenic alopecia is
suggested by the finding of decreased NcoA4a expression
in the outer hair root sheath of balding areas compared with
nonbalding areas, as determined by in situ hybridization
[109]. NcoA4b was reduced in the dermal papilla from the
balding areas. While the role of NcoA4 in male balding
remains speculative, the decrease in NcoA4b associated
with a decline in hair follicles is consistent with the likely
role of this variant in cell proliferation.
Erythrogenesis
During development, blood cells of erythroid, myeloid, and
lymphoid lineages arise from hematopoietic stem cells, and
the regulation of this process by transcription factors is
evolutionarily well conserved. Identification of these fac-
tors has been facilitated by work with zebrafish mutants. In
a whole embryo gene expression analysis of zebrafish
mutants exhibiting various hematopoietic deficits, Weber
et al. [110] identified NcoA4 as upregulated in erythroid
development. This classification of NcoA4 as a potential
erythroid transcription-associated factor is supported by its
high level of expression in developing human red blood
cells. Umbilical cord blood, maternal peripheral blood
cells, and adult blood reticulocytes express high levels of
NcoA4 [111, 112]. Unverified gene expression profiling
studies also indicate that NcoA4 is highly expressed in
human platelets [113]. NcoA4 is also expressed by neu-
trophils and is one of the early genes downregulated by
activation of neutrophils by Escherichia coli K-12 entero-
bacteria [114]. This study also revealed expression of a
large number of transcriptional regulators, including fac-
tors involved with chromatin remodeling, as being rapidly
altered upon neutrophil activation; thus, the decrease in
NcoA4 may participate in this regulation or reflect the
differentiation of these cells.
Perspectives
NcoA4 is a unique protein that lacks well-defined, known
functional domains. The protein is well conserved and
paralogs have not been identified. This lack of diversifi-
cation suggests a conservation of function throughout
metazoan evolution [21]. Substantial evidence indicates
that NcoA4 is an important nuclear receptor coactivator
that undergoes tissue-specific changes in expression dur-
ing development and in association with certain diseases.
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Unlike p160 coactivators, NcoA4 has a predominant
cytoplasmic localization that does not appear to be altered
by treatment with nuclear receptor ligands, suggesting a
unique mechanism of action for this coactivator. Although
NcoA4 has been widely examined for its action as a
coactivator, recent studies show that it associates with
cytoskeletal elements and components of the mitotic
spindle apparatus. This localization suggests activities for
NcoA4 other than that of a nuclear receptor coactivator.
Further studies are required to define these potential actions
in the context of the evolutionary conservation of this
protein.
NcoA4b appears to be emerging as a possible promoter
of cell proliferation, migration, and invasion that may be
involved in cancer progression and metastasis. Thus, it will
be important to delineate the mechanisms underlying dif-
ferential expression of NcoA4 variants and the impact
these isoforms have on non-coactivator functions. Confir-
mation of the importance of NcoA4 to normal and
pathological development is hampered by the lack of a
mouse model with targeted disruption of NcoA4. Moreover,
to our knowledge, NcoA4 has not been the focus of
extensive protein–protein interaction studies. Progress in
these areas is necessary to reveal novel functions of this
protein and to provide a comprehensive understanding of it
physiological role.
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